Pharma’s next growth market isn’t a new drug. It’s an underserved audience.
For decades, pharmaceutical marketing has prioritized scale over specificity, relying on broad campaigns designed to reach the “general market.” But as the United States becomes more diverse and patient expectations evolve, that definition no longer reflects reality.
Today, growth in healthcare is being driven by audiences that have historically been overlooked, particularly Black and multicultural consumers. These communities are disproportionately impacted by many chronic conditions, highly engaged in health decision-making, and increasingly influential in shaping cultural and consumer trends.
Yet, they are still not being reached in ways that feel meaningful or culturally sensitive.
This gap is not just a health equity issue. It’s a missed business opportunity.
The Business Case Has Changed
The U.S. is rapidly becoming more diverse, and with that shift comes a change in where growth will come from.
Black Americans represent more than $1.6 trillion in buying power, according to Nielsen, and account for an estimated $135 billion or more in annual healthcare spending. They also over-index in several high-priority therapeutic areas, including those associated with hypertension, diabetes, and asthma. These are conditions that require long-term management and ongoing engagement with care.
At the same time, multicultural consumers are shaping how health information is consumed, shared, and trusted.
For pharmaceutical companies operating in increasingly competitive categories, growth is no longer just about innovation. It depends on reach, engagement, and ongoing adherence.
And, all of that depends on trust.
The Data: Diverse Audiences Are an Economic Opportunity
Industry data tells a clear story. Diverse audiences are not difficult to reach; they are misunderstood.
Citing research from CMI Media Group, a recent report in MM+M suggests that Black and Hispanic consumers may be more receptive to pharmaceutical advertising than many marketers assume, especially when messaging feels relevant and credible.
Nielsen insights reinforce this. Black consumers demonstrate strong brand loyalty when trust is established and show high engagement across mobile, video, and culturally relevant media environments.
Industry data points to the size of the opportunity. Audience-level insights show what it takes to actually earn it.
The Trust Gap Is the Revenue Gap
Despite the opportunity, trust remains one of the most significant barriers and one of the clearest drivers of growth.
Historical inequities and lived experiences have created both mistrust and distrust in healthcare among Black patients. Mistrust can often be addressed with information. Distrust requires something more dedicated and intentional – consistent, credible engagement over time.
BlackDoctor audience-level insights reinforce this dynamic. They show that trust does not start with messaging. It starts with meeting real needs.
In a 2024 survey of nearly 500 respondents, BlackDoctor found that:
- 74% said lowering the cost of treatment would make pharmaceutical companies more helpful
- More than 55% want tools like doctor visit checklists
- 54% want health information made easier to understand
- Over 40% want ways to track and better understand their symptoms
These are not just feature requests. They are early signs of trust. When patients feel supported and equipped to navigate their care, they are more open to engagement.
Still, meeting needs alone is not enough.
When asked what pharmaceutical companies should do to build trust:
- Nearly 47% said invest more in communities
- 40% called for more Black representation in pharma leadership
- More than 38% want greater visibility in the Black community
- Over 32% said communication should happen through Black-owned media platforms
The message is clear. Trust is built with presence, representation, and helping people in real ways. Messaging alone will not get you there.
You see this even more clearly when trust is broken.
In a separate BlackDoctor audience poll, more than 73% of respondents said they felt troubled or insulted when brands used Black representation in mainstream channels while failing to invest in Black-owned platforms. Many said it reduced their trust.
People are not just listening to what brands say. They are watching where and how they show up.
This is where business impact becomes clear.
If patients do not trust the message, they are less likely to seek care, start treatment, and/or stick to their treatment plan.
That directly influences ongoing-adherence and, ultimately, revenue. Medication non-adherence alone is estimated to cost the U.S. healthcare system more than $300 billion annually.
If trust drives adherence, and adherence drives revenue, then trust directly impacts the bottom line.
Why Pharma Has Missed the Mark
Despite growing awareness around diversity, equity, and inclusion, many pharmaceutical marketing strategies have yet to fully evolve.
Analysis from Pharmaceutical Executive points to a familiar pattern. There is strong intent, but inconsistent execution, especially when it comes to embedding cultural nuance into marketing and engagement strategies.
Too often, Black and Brown audiences are treated as secondary segments or campaign extensions, rather than core drivers of growth.
At the same time, many brands continue to rely on broad “general market” approaches, even as the market becomes more culturally defined.
In many cases, the gap is not awareness. It is execution.
Pharma has scaled its messaging. It has not scaled its credibility.
What Winning Looks Like
For pharmaceutical companies looking to unlock this opportunity, success requires a shift in mindset and strategy.
1. Invest in Trusted Platforms
Trust cannot be manufactured. It has to be built or strengthened through the right partnerships. More brands are recognizing the value of culturally rooted platforms, like BlackDoctor which has spent over 20 years earning credibility through consistent, community-centered engagement with both audiences and the healthcare professionals (HCPs) who serve them.
These environments operate differently than traditional media. They do more than deliver impressions. They help shape and influence real decisions over time.
2. Move Beyond Awareness to Education
Patients are not just looking for messaging. They are looking for guidance.
Content that is practical, culturally relevant, and easy to understand – whether it is checklists, explainers, or real patient stories – creates a clear path from awareness to action. Platforms are also beginning to use tools like AI to make that guidance more accessible, delivering information in ways that reflect the audience and the healthcare professionals they trust. When done well, these tools can help people better navigate complex conversations and feel more confident in their decisions.
3. Reflect the Audience Authentically
Representation matters, but relatability is what makes it stick. Messaging needs to reflect lived experiences, cultural context, and real-world concerns to truly resonate. People want to see themselves in the story and feel understood, not marketed to. That means creating content that is not only accurate, but culturally relevant, grounded in real experiences and delivered in environments where people feel safe learning about their health. When this happens the message doesn’t just land. It builds trust and encourages action.
4. Measure What Matters
Traditional metrics like impressions and reach only tell part of the story.
Leading organizations are focusing on indicators that reflect real impact:
- Engagement
- Treatment initiation
- Ongoing-Adherence
- Long-term trust
The Competitive Advantage
The pharmaceutical companies that lead in the next decade will not simply be those with the most innovative pipelines.
They will be the ones who understand how to build trust and sustain it.
When engagement is rooted in trust, the impact goes further. It influences decision-making, strengthens relationships, and drives long-term value.
The future of pharmaceutical marketing is not broader. It is more precise, more culturally sensitive, and more human.
And for the companies willing to embrace that shift, the opportunity is not just to reach more patients by spending marketing dollars on general market platforms.
It is to meet them where they are, where trust already exists with the brands who know and can reach these diverse audiences better and where action is far more likely to follow.
Sources include: Nielsen Diverse Intelligence Series; MM+M (CMI Media Group research); Pharmaceutical Executive; Annals of Internal Medicine; WHO; CDC; CMS; KFF; and proprietary audience insights from BlackDoctor.com.